Prescriby is an Icelandic–Canadian health technology company that builds a clinician‑facing treatment‑management platform to prevent and manage dependence on prescription opioids and other addictive medications by delivering clinician‑created tapering plans, remote monitoring, and clinical decision support tools for safer prescribing and tapering workflows[1][2][5].
High‑Level Overview
- Mission: Prescriby’s stated mission is to reduce harm from addictive prescription medications by operationalizing clinically validated treatment protocols and providing software that helps clinicians prescribe more safely and taper patients off addictive drugs when needed[5][1].
- Investment philosophy: (Not an investment firm; instead recently raised growth funding — Prescriby closed a ~€2M round led by Crowberry Capital to scale in Canada and enter the U.S. clinical decision‑support market)[1][2].
- Key sectors: Digital health, clinical decision support, addiction management, and telehealth for prescription medication management[1][3][5].
- Impact on the startup ecosystem: By focusing on early intervention for prescription‑drug dependence and embedding protocolized care into clinician workflows, Prescriby adds to the emerging cohort of startups moving upstream of addiction treatment toward prevention and clinician tools, and it demonstrates how small med‑tech/health‑software companies can scale via public‑sector partnerships and targeted clinical trials[2][1].
For a portfolio company view (product & customers)
- Product it builds: A secure, clinician‑driven treatment management platform that creates and distributes tapering plans, supports remote patient monitoring, and provides clinical decision support for prescribing and tapering addictive medications[5][1].
- Who it serves: Clinicians and healthcare systems (examples include a nationwide implementation partnership with the Icelandic Ministry of Health and commercialization efforts in Canada), and ultimately patients on long‑term or high‑risk prescriptions[1][2].
- What problem it solves: Lack of tools and standardized workflows for safe initiation, monitoring, and tapering of addictive prescriptions — aiming to prevent addiction rather than only treating it after it develops[2][1].
- Growth momentum: Prescriby raised approximately €2M in 2024 led by Crowberry Capital, launched a nationwide project in Iceland, began commercialization in Canada, and planned controlled clinical trials in Denmark while preparing U.S. market entry as a clinical decision support tool[1][2].
Origin Story
- Founding and founders: Prescriby was co‑founded by Dr. Kjartan Thorsson (CEO) and others with clinical experience in perioperative prescribing and opioid management; the idea originated from clinical practice at the University Hospital of Iceland where Thorsson saw frequent opioid discharges and recognized a lack of prescriber tools to reduce risk of dependence[1].
- How the idea emerged: Clinical experience observing that roughly one in ten post‑operative patients could develop some level of addiction led to designing a software workflow to apply existing tapering protocols and remote monitoring in routine care[1][5].
- Early traction / pivotal moments: Partnership with the Icelandic Ministry of Health for nationwide implementation, commercialization projects in Canada, initiation of a controlled cohort clinical trial in Denmark, and a €2M funding round to enable scaling into Canada and the U.S.[1][2].
Core Differentiators
- Clinical protocolization: Software embeds and operationalizes existing, clinically validated tapering and opioid‑stewardship protocols rather than offering a generic medication app[5].
- Clinician‑centered workflow: The platform allows clinicians to *create* tapering plans and *release* them to patients for remote monitoring, keeping clinicians central to decision making and follow‑up[1][5].
- Public‑sector partnerships and evidence generation: Early adoption at national scale in Iceland and planned controlled trials (Denmark) provide institutional validation beyond purely commercial pilots[1][2].
- Focus on prevention: Unlike many digital health players that emphasize addiction treatment, Prescriby explicitly focuses on early intervention and safer prescribing to prevent dependence from developing[2].
- Compact, targeted funding strategy: A modest institutional round (~€2M) led by a Nordic VC positions the company to scale in selected geographies while pursuing clinical validation[1].
Role in the Broader Tech Landscape
- Trend alignment: Prescriby rides the convergence of digital health, telemedicine, and clinical decision support, addressing a rising public‑health crisis (opioid‑related harm) with technology that augments clinician workflows[2][5].
- Timing: With opioid‑related deaths and synthetic opioids (e.g., fentanyl) driving urgent policy and clinical attention, tools that help prevent iatrogenic addiction are in growing demand among health systems and payers[2].
- Market forces in their favor: Regulatory and payer interest in harm‑reduction, increased funding for digital therapeutics/clinical‑decision tools, and health systems' appetite for scalable protocols support adoption[1][2].
- Influence on ecosystem: By demonstrating that protocolized, clinician‑led digital tools can be deployed at national scale and evaluated in controlled trials, Prescriby could influence standards for prescription management and encourage other startups to prioritize prevention and clinician integration[1][2].
Quick Take & Future Outlook
- Near term outlook: Expect focused expansion in Canada and initial U.S. market entry as a clinical decision support tool, continued clinical evidence generation (Denmark cohort trial), and further public‑sector rollouts if early results validate efficacy and cost savings[1][2][5].
- Trends that will shape Prescriby’s path: Continued policy emphasis on opioid stewardship, reimbursement models that reward harm reduction and care‑coordination, and the need for real‑world evidence to secure broader health system adoption.
- Potential evolution of influence: If clinical trials and national pilots show measurable reductions in dependence or costs, Prescriby could become a standard module in perioperative and chronic‑pain prescribing workflows or be integrated into electronic health record ecosystems. Conversely, scaling will require navigating regulatory variability across jurisdictions and proving cost‑effectiveness to payers and health systems[1][2][5].
Quick take: Prescriby targets a clear and urgent gap — safer initiation and tapering of addictive prescriptions — and has early validation via government partnerships and VC backing; its next critical milestones are clinical trial outcomes and demonstration of scalable ROI that enable broader adoption across North America and Europe[1][2][5].
